Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clopidogrel pathway.

Literature DB >> 20440227

Clopidogrel pathway.

Katrin Sangkuhl¹, Teri E Klein, Russ B Altman.

Abstract

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2010 PMID： 20440227 PMCID： PMC3086847 DOI： 10.1097/FPC.0b013e3283385420

Source DB: PubMed Journal: Pharmacogenet Genomics ISSN： 1744-6872 Impact factor: 2.089

× No keyword cloud information.

29 in total

1. Identification and biological activity of the active metabolite of clopidogrel.

Authors: P Savi; J M Pereillo; M F Uzabiaga; J Combalbert; C Picard; J P Maffrand; M Pascal; J M Herbert
Journal: Thromb Haemost Date: 2000-11 Impact factor: 5.249

2. Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between?

Authors: Mary K Rude; William D Chey
Journal: Gastroenterology Date: 2009-07-25 Impact factor: 22.682

3. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.

Authors: Thomas A Clarke; Lucy A Waskell
Journal: Drug Metab Dispos Date: 2003-01 Impact factor: 3.922

4. Pharmacokinetic profile of 14C-labeled clopidogrel.

Authors: R Lins; J Broekhuysen; J Necciari; X Deroubaix
Journal: Semin Thromb Hemost Date: 1999 Impact factor: 4.180

5. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors: Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal: JAMA Date: 2009-08-26 Impact factor: 56.272

6. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Authors: Betti Giusti; Anna Maria Gori; Rossella Marcucci; Claudia Saracini; Ilaria Sestini; Rita Paniccia; Serafina Valente; Davide Antoniucci; Rosanna Abbate; Gian Franco Gensini
Journal: Pharmacogenet Genomics Date: 2007-12 Impact factor: 2.089

7. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors: Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal: Lancet Date: 2008-12-26 Impact factor: 79.321

8. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.

Authors: Wei C Lau; Lucy A Waskell; Paul B Watkins; Charlene J Neer; Kevin Horowitz; Amy S Hopp; Alan R Tait; David G M Carville; Kirk E Guyer; Eric R Bates
Journal: Circulation Date: 2003-01-07 Impact factor: 29.690

9. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.

Authors: Jacqueline Saw; Steven R Steinhubl; Peter B Berger; Dean J Kereiakes; Victor L Serebruany; Danielle Brennan; Eric J Topol
Journal: Circulation Date: 2003-08-18 Impact factor: 29.690

10. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

Authors: P Michael Ho; Thomas M Maddox; Li Wang; Stephan D Fihn; Robert L Jesse; Eric D Peterson; John S Rumsfeld
Journal: JAMA Date: 2009-03-04 Impact factor: 56.272

58 in total

1. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.

Authors: A L Beitelshees; R B Horenstein; M R Vesely; M R Mehra; A R Shuldiner
Journal: Clin Pharmacol Ther Date: 2011-01-26 Impact factor: 6.875

2. Prophylactic Antiplatelet Medication in Endovascular Treatment of Intracranial Aneurysms: Low-Dose Prasugrel versus Clopidogrel.

Authors: E J Ha; W S Cho; J E Kim; Y D Cho; H H Choi; T Kim; J S Bang; G Hwang; O K Kwon; C W Oh; M H Han; H S Kang
Journal: AJNR Am J Neuroradiol Date: 2016-07-07 Impact factor: 3.825

Review 3. Potential for developing purinergic drugs for gastrointestinal diseases.

Authors: Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal: Inflamm Bowel Dis Date: 2014-07 Impact factor: 5.325

Review 4. Antiplatelet drug interactions with proton pump inhibitors.

Authors: Stuart A Scott; Aniwaa Owusu Obeng; Jean-Sébastien Hulot
Journal: Expert Opin Drug Metab Toxicol Date: 2013-11-09 Impact factor: 4.481

Review 5. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Authors: Yao Yang; Joshua P Lewis; Jean-Sébastien Hulot; Stuart A Scott
Journal: Expert Opin Drug Metab Toxicol Date: 2015-07-14 Impact factor: 4.481

6. Deciphering glycomics and neuroproteomic alterations in experimental traumatic brain injury: Comparative analysis of aspirin and clopidogrel treatment.

Authors: Hussein Abou-Abbass; Hisham Bahmad; Hadi Abou-El-Hassan; Rui Zhu; Shiyue Zhou; Xue Dong; Eva Hamade; Khalil Mallah; Abir Zebian; Naify Ramadan; Stefania Mondello; Jawad Fares; Youssef Comair; Samir Atweh; Hala Darwish; Kazem Zibara; Yehia Mechref; Firas Kobeissy
Journal: Electrophoresis Date: 2016-03-29 Impact factor: 3.535

7. Clopidogrel IBS Patients Have Higher Incidence of Gastrointestinal Symptoms Influenced by Age and Gender.

Authors: Suren Soghomonyan; Mahmoud Abdel-Rasoul; Alix Zuleta-Alarcon; Iveta Grants; Victor Davila; Jeffrey Yu; Cheng Zhang; Emmett E Whitaker; Sergio D Bergese; Nicoleta Stoicea; Razvan Arsenescu; Fievos L Christofi
Journal: Dig Dis Sci Date: 2017-08-24 Impact factor: 3.199